Siga Technologies (SIGA) Stock Price, News & Analysis

Company Overview

Siga Technologies, Inc. (NASDAQ: SIGA) is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of medical countermeasures for public health emergencies and biological threats. The company’s flagship product, TPOXX® (tecovirimat), is the first and only antiviral approved by the U.S. Food and Drug Administration for the treatment of smallpox. Siga has entered into procurement and development contracts with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense, to supply TPOXX® for the Strategic National Stockpile.

Founded in 2002, Siga has built a pipeline of therapies targeting high-consequence pathogens such as smallpox, plague and other potential biothreat agents. In addition to its commercial-stage TPOXX® program, the company is advancing earlier-stage candidates and manufacturing capabilities to support rapid scale-up in emergency scenarios. Siga’s research and development efforts draw on proprietary formulations and delivery technologies designed to meet stringent regulatory and biodefense requirements.

Headquartered in Corvallis, Oregon, with additional offices in New York, Siga serves government and public health agencies in North America and Europe. The company maintains a state-licensed manufacturing facility capable of producing large-scale quantities of its antiviral products. Through collaborations with international health organizations, Siga contributes to global preparedness initiatives for emerging viral diseases, including recent efforts around monkeypox and other orthopoxviruses.

Siga Technologies is led by a management team with extensive experience in pharmaceuticals, biodefense and regulatory affairs. The company holds multiple U.S. and international patents covering its antiviral compounds and formulations, positioning it as a key supplier of strategic medical countermeasures in both government stockpiles and broader public health programs.

Key Stats

• Today's Range: $4.09 to $4.31
• 50-Day Range: $4.17 to $6.24
• 52-Week Range: $4.09 to $9.62
• Volume: 700,053 shs
• Average Volume: 467,917 shs
• Market Capitalization: $299.07 million
• P/E Ratio: 15.44
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Siga Technologies Stock Analysis - MarketRank™

Siga Technologies scored higher than 21% of companies evaluated by MarketBeat, and ranked 790th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Siga Technologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Siga Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Siga Technologies is 15.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.54.

Price to Earnings Ratio vs. Sector

The P/E ratio of Siga Technologies is 15.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.62.

Price to Book Value per Share Ratio

Siga Technologies has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.78% of the float of Siga Technologies has been sold short.

Short Interest Ratio / Days to Cover

Siga Technologies has a short interest ratio ("days to cover") of 8.16.

Change versus previous month

Short interest in Siga Technologies has recently increased by 3.09%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Siga Technologies does not currently pay a dividend.

Dividend Growth

Siga Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.41

News Sentiment

Siga Technologies has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Siga Technologies this week, compared to 1 article on an average week.

Search Interest

Only 9 people have searched for SIGA on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.

MarketBeat Follows

2 people have added Siga Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Siga Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.73% of the stock of Siga Technologies is held by insiders.

Percentage Held by Institutions

55.40% of the stock of Siga Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 4/23 Dividend: 4/07/2026
• Ex-Dividend for 4/23 Dividend: 4/07/2026
• Dividend Payable: 4/23/2026
• Last Earnings: 5/07/2026
• Today: 5/16/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SIGA
• CIK: 1010086
• Web: www.siga.com
• Phone: (212) 672-9100
• Fax: 212-697-3130
• Employees: 40
• Year Founded: 1995

Profitability

• EPS (Trailing Twelve Months): $0.27
• Trailing P/E Ratio: 15.44
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $23.28 million
• Net Margins: 21.58%
• Pretax Margin: 28.69%
• Return on Equity: 10.60%
• Return on Assets: 8.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.25
• Quick Ratio: 9.10

Sales & Book Value

• Annual Sales: $94.57 million
• Price / Sales: 3.16
• Cash Flow: $0.33 per share
• Price / Cash Flow: 12.52
• Book Value: $2.11 per share
• Price / Book: 1.98

Miscellaneous

• Outstanding Shares: 71,720,000
• Free Float: 69,766,000
• Market Cap: $299.07 million
• Optionable: Optionable
• Beta: 0.93